LivaNova (NASDAQ:LIVN) Releases Earnings Results, Beats Estimates By $0.20 EPS

LivaNova (NASDAQ:LIVN) issued its earnings results on Wednesday. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.20, Briefing.com reports. The business had revenue of $357.80 million for the quarter, compared to analyst estimates of $342.32 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period last year, the company posted $0.90 earnings per share. LivaNova updated its FY 2025 guidance to 3.800-3.90 EPS.

LivaNova Stock Down 2.4%

NASDAQ LIVN traded down $1.24 on Thursday, hitting $49.57. The stock had a trading volume of 422,042 shares, compared to its average volume of 665,910. The business’s fifty day moving average price is $54.25 and its 200 day moving average price is $48.13. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. LivaNova has a 52-week low of $32.48 and a 52-week high of $58.91. The stock has a market cap of $2.71 billion, a price-to-earnings ratio of -12.74 and a beta of 1.00.

Wall Street Analyst Weigh In

LIVN has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LivaNova in a research report on Wednesday, October 8th. The Goldman Sachs Group set a $55.00 price objective on shares of LivaNova and gave the company a “neutral” rating in a report on Wednesday, October 1st. Robert W. Baird lifted their price objective on shares of LivaNova from $61.00 to $63.00 and gave the company an “outperform” rating in a report on Thursday. Barclays lifted their price objective on shares of LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Finally, Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of LivaNova in a report on Wednesday, September 3rd. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Institutional Investors Weigh In On LivaNova

Institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after purchasing an additional 1,360 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of LivaNova by 4.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock worth $32,012,000 after acquiring an additional 36,094 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of LivaNova by 10.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after acquiring an additional 15,405 shares during the last quarter. Intech Investment Management LLC lifted its holdings in LivaNova by 19.6% during the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock worth $1,724,000 after buying an additional 7,195 shares in the last quarter. Finally, Strs Ohio acquired a new stake in LivaNova during the 1st quarter worth approximately $130,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.